System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Research Support, Non-U.S. Gov't Ppublish 10 citations

PubMed: 40302169 DOI: 10.1111/irv.70105

Impact of Nirsevimab on RSV and Non-RSV Severe Respiratory Infections in Hospitalized Infants.

Influenza Other Respir Viruses 19(5):e70105

Authors: María Luz García-García, Patricia Alonso-López, Sonia Alcolea, M Arroyas, Francisco Pozo, Inmaculada Casas, Maria Iglesias-Caballero, Rocío Sánchez-León, Jara Hurtado-Gallego, Cristina Calvo

Affiliations

  • Pediatrics Department, Severo Ochoa University Hospital, Leganés, Spain.
  • Puerta de Hierro Institute for Health Research (IDIPHISA), Majadahonda, Spain.
  • Center for Biomedical Research in the Infectious Diseases Network (CIBERINFEC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
  • Reference and Research Laboratory for Respiratory Virus, National Centre for Microbiology, Instituto de Salud Carlos III (ISCIII), Majadahonda, Madrid, Spain.
  • CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
  • Pediatric Infectious and Tropical Diseases Department, La Paz University Hospital. La Paz Institute for Health Research (IdiPAZ), P° de la Castellana, Madrid, Spain.
  • European Society For Paediatric Infectious Diseases (ESPID), Seafield, UK.

Abstract

BACKGROUND

Nirsevimab, a monoclonal antibody providing passive immunity against RSV infections in infants, was introduced in Spain in October 2023 for children under 6 months and those born during the epidemic season. This study aimed to compare the clinical and virological characteristics of respiratory infections in hospitalized infants before and after nirsevimab introduction.

METHODS

We carried out a prospective study across two hospitals in Madrid during the 2022-2023 and 2023-2024 epidemic seasons. The study included infants under 12 months of age that were hospitalized with lower respiratory tract infections (LRTIs). Clinical, epidemiological, and virological data were analyzed and compared between the periods before and after the introduction of nirsevimab, as well as according to whether the infants had received this preventive treatment.

RESULTS

A total of 669 infants were included: 480 from October 2022 to March 2023 (S1) and 189 from October 2023 to March 2024 (S2). Respiratory infection-related admissions decreased by 62.5% in S2, with a 74.5% reduction in ICU admissions. RSV-related admissions decreased by 78%, HMPV by 36.6%, and adenovirus by 69.5%. Infants in S2 were older (p = 0.001) and had shorter hospital stays (p < 0.001) than in S1. Of 63 (33%) infants in S2 who received nirsevimab, 11 (17%) were diagnosed with RSV. High-flow oxygen use was less frequent among RSV patients treated with nirsevimab (p = 0.002).

CONCLUSIONS

Nirsevimab introduction was significantly associated with reduced hospitalizations and severity of RSV and other respiratory infections. Its use was associated with fewer admissions and reduced need for intensive care, especially in RSV-infected infants but also in HMPV and adenovirus-infected infants.

MeSH

Respiratory Syncytial Viruses, Adenoviridae, Respiratory Tract Infections, Influenza, Human, Bronchiolitis, Epidemics, Infections, Infant

Cited by